

Special Issue

Mucosal Responses in the Context of Natural Immunity to HIV

Message from the Guest Editor

Approximately 37 million people are living with HIV/AIDS worldwide. Most HIV infections are acquired through heterosexual intercourse, and in Africa, nearly 60% of new infections affect women. Currently, there is no cure and the development of vaccines and microbicides remains the best solution to eradicate the pandemic. To this end, the development of effective devices will benefit from studies of individuals who are highly-exposed to HIV and yet remain seronegative (HESN) despite several years of exposure. This special issue aims to further our comprehension of the immune responses that govern mucosal ports of entry in individuals presenting natural immunity to HIV. We therefore encourage the presentation of recent advances in this field. Lessons from vaccination trials and passive immunization studies, and those with non-human primates will also be welcome. Understanding the nature and how immune populations are recruited and maintained within mucosal niche to fight HIV is important to the design of effective preventive/therapeutic approaches.

Guest Editor

Dr. Johanne Poudrier

Département de Microbiologie, Infectiologie et Immunologie, Université de Montréal, Montréal, QC, Canada

Deadline for manuscript submissions

closed (31 January 2021)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/50438

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).